F-1/A: Haoxi Health Technology Eyes $14.4 Million in Unit Offering, Including Warrants

Haoxi Health Technology plans to raise capital through a unit offering consisting of Class A Ordinary Shares and warrants, aiming for approximately $14.4 million if the over-allotment option is fully exercised.

Summary

• Haoxi Health Technology Limited is planning a firm commitment offering of 3,306,878 units, with an option for underwriters to purchase an additional 496,031 units to cover over-allotments.
• Each unit comprises one Class A Ordinary Share (or a pre-funded warrant), one Series A warrant, and one Series B warrant.
• The assumed public offering price is $3.78 per unit, based on the last reported sale price on Nasdaq on July 23, 2024.
• The pre-funded warrants are exercisable upon issuance at $0.0001 per share and do not expire until fully exercised.
• Series A warrants have a 5-year term, are exercisable upon issuance with an initial exercise price of $3.78, subject to reset on the 16th Trading Day.
• On the Reset Date, the exercise price of the Series A Warrant will be adjusted to $0.756, and the number of shares issuable will be adjusted to 16,534,392 shares, assuming an offering price of $3.78 per Unit.
• Series B warrants have a 5-year term and are exercisable after the Reset Date at $0.0001 per share.
• On the Reset Date, the number of shares issuable upon exercise of the Series B warrants will be increased to 13,227,513 shares, based on an assumed offering price of $3.78 per Unit.
• The maximum number of Class A Ordinary Shares underlying the Series A and Series B warrants would be approximately 16,534,392 and 13,227,513, respectively, assuming an offering price of $3.78 per Unit.
• The company has granted EF Hutton LLC an option to purchase up to 15% of the total number of units offered for over-allotments.
• The company intends to submit its filing application to the CSRC within three working days after the completion of this offering.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The company is growing and has plans for future expansion, but it also faces regulatory risks and uncertainties related to operating in China. The complex warrant structure adds a layer of risk for investors.

Positives

• The offering aims to strengthen the company's financial position for future growth.
• The company has a management team with several years of experience in marketing for healthcare companies.
• The company has developed a stable placement with mainstream online advertising platforms in China and has been working closely with them since its establishment in 2018.

Negatives

• There is no established trading market for the Units or the Warrants.
• The Warrants in this offering are speculative in nature.
• The company is subject to regulatory risks associated with operating in China, including CSRC filing requirements.
• The company is an emerging growth company and may take advantage of certain exemptions from disclosure requirements.

Risks

• Investing in the company's Class A Ordinary Shares involves a high degree of risk.
• The company is subject to legal and operational risks associated with business operations in China.
• The Chinese regulatory authorities could disallow the company's corporate structure.
• The CSRC filing procedures could significantly limit or completely hinder the company's ability to offer or continue to offer its Class A Ordinary Shares to investors.
• The company's Class A Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act.
• The company may need dividends and other distributions on equity paid by Haoxi Beijing to satisfy its liquidity requirements.
• The company may be treated as a resident enterprise for PRC tax purposes under the PRC Enterprise Income Tax Law.
• The company and its shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.
• Restrictions on currency exchange may limit the company's ability to utilize its revenue effectively.
• The company is exposed to concentration risk, due to its reliance on its major supplier, Ocean Engine.
• The company's plan to invest in research and development (R&D) of Bidding Compass, may fail to result in a satisfactory return, or any return.

Future Outlook

The company intends to use the proceeds from this offering for working capital and general corporate purposes, acquiring or investing in technologies, solutions or businesses that complement its business, and hiring experienced employees to improve its systems of internal control and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002.

Industry Context

The company operates in the online marketing solution industry in China, with a focus on the healthcare sector. The growth of the company is influenced by the increasing adoption of news feed ads and the development of the healthcare industry in China.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To accurately assess Haoxi Health Technology's performance against industry benchmarks, we would need to compare its key financial metrics (revenue growth, profit margins, customer acquisition cost, etc.) with those of its direct competitors in the Chinese online marketing and healthcare advertising space.
• Some potential comparable companies could include: Baidu (BIDU): A leading Chinese search engine and online advertising platform.
• Tencent (0700.HK): A major player in social media and online advertising, particularly through WeChat.
• Sina Weibo (WB): A popular Chinese microblogging platform with a significant advertising presence.
• iClick Interactive Asia Group Limited (ICLK): A marketing technology company focused on the Chinese market.
• However, without specific data on these companies' performance in the healthcare advertising segment, a direct comparison is difficult.
• Additionally, industry reports from sources like iResearch or Analysys International could provide broader benchmarks for the growth rate and profitability of the Chinese online advertising market.

Stakeholder Impact

• Shareholders face potential dilution and risks associated with the company's operations in China.
• Employees may benefit from the company's growth and expansion plans.
• Customers may benefit from improved online marketing solutions.
• Suppliers may see increased business from the company's operations.
• Creditors face risks associated with the company's ability to repay debts.

Next Steps

• The company will submit its filing application to the CSRC within three working days after the completion of this offering.
• The company intends to use the proceeds from this offering for working capital and general corporate purposes, acquiring or investing in technologies, solutions or businesses that complement its business, and hiring experienced employees to improve its systems of internal control and compliance with U.S. GAAP and the Sarbanes-Oxley Act of 2002.

Key Dates

Keywords

Units, Class A Ordinary Shares, Warrants, Offering, Haoxi Health Technology, CSRC, EF Hutton, China, Healthcare, Investment